Insider Selling: Prestige Consumer Healthcare Inc. (NYSE:PBH) EVP Sells 9,063 Shares of Stock

Prestige Consumer Healthcare Inc. (NYSE:PBH) EVP Adel Mekhail sold 9,063 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the sale, the executive vice president now owns 18,365 shares of the company’s stock, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $82.36 on Friday. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare Inc. has a 12 month low of $56.61 and a 12 month high of $83.83. The company’s fifty day moving average is $73.13 and its 200-day moving average is $70.18. The firm has a market cap of $4.07 billion, a price-to-earnings ratio of 20.04, a price-to-earnings-growth ratio of 2.32 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. The company had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The business’s revenue was down .9% compared to the same quarter last year. During the same period last year, the company earned $1.07 earnings per share. Equities analysts expect that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on PBH shares. Jefferies Financial Group reiterated a “hold” rating and set a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. DA Davidson reaffirmed a “buy” rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $83.67.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of large investors have recently added to or reduced their stakes in PBH. Ariel Investments LLC lifted its stake in shares of Prestige Consumer Healthcare by 10.7% in the second quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock worth $195,204,000 after buying an additional 274,212 shares during the last quarter. Victory Capital Management Inc. raised its holdings in Prestige Consumer Healthcare by 9.0% in the 2nd quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock worth $142,827,000 after acquiring an additional 171,357 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Prestige Consumer Healthcare by 19.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company’s stock worth $113,570,000 after acquiring an additional 255,045 shares during the last quarter. Congress Asset Management Co. boosted its holdings in Prestige Consumer Healthcare by 7.8% during the third quarter. Congress Asset Management Co. now owns 865,123 shares of the company’s stock valued at $62,375,000 after acquiring an additional 62,411 shares during the period. Finally, Boston Trust Walden Corp acquired a new stake in shares of Prestige Consumer Healthcare in the third quarter valued at about $41,785,000. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.